[AMRN] Amarin Corporation plc

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 3.11 Change: 0.12 (4.01%)
Ext. hours: Change: 0 (0%)

chart AMRN

Refresh chart

Strongest Trends Summary For AMRN

AMRN is in the long-term up 420% in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases in the United States. It develops products in the areas of lipid science and therapeutic benefits of polyunsaturated fatty acids. The company markets Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. It is also developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-0.33 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 26.39% Sales Growth - Q/Q-3.32% P/E-8.88
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-28.56% ROE99.49% ROI-38.89%
Current Ratio4.46 Quick Ratio4.08 Long Term Debt/Equity1.49 Debt Ratio-0.69
Gross Margin63.04% Operating Margin-164.67% Net Profit Margin-103.96% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities54.3 M Cash From Investing Activities Cash From Operating Activities-12.64 M Gross Profit10.31 M
Net Profit-31.13 M Operating Profit-27.05 M Total Assets215.34 M Total Current Assets189.75 M
Total Current Liabilities42.53 M Total Debt233.48 M Total Liabilities277.16 M Total Revenue15.93 M
Technical Data
High 52 week23.16 Low 52 week12.41 Last close15.86 Last change2.65%
RSI49.7 Average true range0.66 Beta0.52 Volume2.65 M
Simple moving average 20 days3.48% Simple moving average 50 days1.83% Simple moving average 200 days-10.53%
Performance Data
Performance Week12.08% Performance Month-8.06% Performance Quart-24.73% Performance Half-13.76%
Performance Year-19.29% Performance Year-to-date16.53% Volatility daily2.47% Volatility weekly5.52%
Volatility monthly11.31% Volatility yearly39.17% Relative Volume527.59% Average Volume7.79 M
New High New Low

News

2019-11-15 16:32:08 | This Biotech Stock Broke Out Bullishly On A Key FDA Recommendation

2019-11-15 15:04:19 | Analyst: Peak Sales Potential Of Amarin's Vascepa Underappreciated

2019-11-15 10:09:21 | The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval

2019-11-15 09:57:31 | Dow Jones Today Opens Higher On China Trade Hopes; Apple Gets Price Target Hikes; These 4 Stocks May Offer Buys

2019-11-15 09:47:28 | Amarin Stock Jumps as Debate Moves to Heart Drug’s Potential Label

2019-11-15 09:22:08 | This Fish-Oil Heart Drug Will Be Big, Could Be Huge

2019-11-15 09:10:02 | Amarin AMRN Gets FDA Panel Nod for Vascepa Label Expansion

2019-11-15 08:54:00 | Amarin Stock Is Rising After Favorable Vote on Fish-Based Heart Drug

2019-11-15 08:25:00 | Amarin shares rise in premarket trading on FDA adcom vote for new label

2019-11-15 06:30:00 | HLS Therapeutics Reports on U.S. FDA Advisory Committee Recommendation for Vascepa

2019-11-14 22:44:42 | Dow Jones Futures Rise With China Trade Deal 'Close': Applied Materials, RH Lead 5 Stocks With Big News

2019-11-14 17:34:37 | Amarin Announced FDA Advisory Committee Voted Unanimously 16-0 to Recommend Approval of Vascepa® icosapent ethyl Capsules Label Expansion to Reduce Cardiovascular Risk Based on Landmark REDUCE-IT® Outcomes Trial

2019-11-14 17:03:25 | Will A Positive FDA Committee Vote Send This Biotech Into A Breakout?

2019-11-14 16:59:00 | Amarin’s Fish-Based Cardiovascular Drug Gets Thumbs Up From FDA Committee

2019-11-14 16:32:08 | Amarin Wins FDA Panel Nod to Expand Heart Drug Vascepa’s Label

2019-11-14 16:30:18 | UPDATE 2-FDA panel unanimously backs expanding use of Amarin's heart drug Vascepa

2019-11-14 15:05:15 | Amarin's Vascepa Adcom Meeting: What You Need To Know

2019-11-14 13:27:00 | AMD, Amarin and Crispr are three stocks to watch for potentially higher prices

2019-11-14 08:44:59 | Benzinga Pro's Top 5 Stocks To Watch For Thurs., Nov. 14, 2019: NVDA, SINA, DDS, TROV, AMRN

2019-11-14 08:18:00 | Amarin Stock Trading Is Halted for FDA Meeting on Fish-Based Cardiovascular Drug

2019-11-14 08:07:04 | The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing

2019-11-14 07:23:00 | Amarin shares halted ahead of FDA committee meeting for its only drug

2019-11-14 06:59:25 | Amarin Corporation plc NASDAQ:AMRN Stock Trading Halted Today for Scheduled FDA Advisory Committee Review of sNDA Seeking New Indication for Vascepa® Icosapent Ethyl to Reduce the Risk of Major Adverse Cardiovascular Events Based on Landmark REDUCE-IT® Ca

2019-11-13 15:43:08 | Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates

2019-11-13 10:38:00 | Amarin’s Cardiovascular Drug Faces a Key Test Tomorrow. What It Means for the Stock.

2019-11-13 10:00:03 | What Makes Amarin AMRN a Strong Momentum Stock: Buy Now?

2019-11-12 16:00:01 | This Biotech Just Gapped Up As FDA Mulls A Second Use For Its Medicine

2019-11-12 15:48:03 | 5 Top Stock Trades for Wednesday: SPY, DIS, PYPL

2019-11-12 14:41:00 | Amarin shares rise 21% ahead of FDA committee meeting for its only drug

2019-11-12 11:28:44 | Amarin Shares Climb Following In-Line Review Of Fish Oil Pill By FDA Staffers

2019-11-12 10:03:00 | Shares of Amarin rise on favorable opinion from FDA committee

2019-11-12 08:45:03 | Benzinga Pro's Top 5 Stocks To Watch For Tues., Nov. 12, 2019: BUD, AMRN, ROK, OGI, LK

2019-11-11 13:19:57 | New Analysis Shows Icosapent Ethyl Vascepa® Is Cost Effective and Offers Rare Finding of Better Outcomes at Lower Healthcare Costs When Used to Treat High-Risk Patients with Cardiovascular Disease or Diabetes and Other Risk Factors

2019-11-11 06:30:48 | REDUCE-IT® USA Results, in Prespecified Subgroup Analyses of Landmark REDUCE-IT Global Study, Showed Robust Cardiovascular Risk Reductions Across a Variety of Study Endpoints, Including Cardiovascular Death and All-Cause Mortality

2019-11-11 05:00:00 | Amarin to Present at the Jefferies 2019 London Healthcare Conference

2019-11-10 16:08:20 | The Week Ahead In Biotech: Adcom Test For Amarin's Fish Oil Pill, Agile Awaits FDA Verdict

2019-11-08 09:30:02 | Has Amarin Corporation AMRN Outpaced Other Medical Stocks This Year?

2019-11-07 18:07:22 | There’s an Opportunity Brewing in Amarin AMRN Stock Ahead of Vascepa’s AdCom, Says Analyst

2019-11-05 20:09:14 | Edited Transcript of AMRN earnings conference call or presentation 5-Nov-19 12:30pm GMT

2019-11-05 05:30:00 | Amarin Corp. Plc to Host Earnings Call

2019-11-05 05:00:00 | Amarin Reports Third Quarter 2019 Financial Results and Provides Update on Operations

2019-11-04 11:42:04 | What's in the Cards for Zynerba ZYNE This Earnings Season?

2019-11-04 06:00:00 | Seven Data Presentations Relevant to Vascepa® Icosapent Ethyl Capsules and Persistent Cardiovascular Risk to be Presented at American Heart Association’s 2019 Scientific Sessions, November 16 – 18

2019-11-01 10:41:02 | What's in the Cards for Perrigo PRGO This Earnings Season?

2019-10-31 17:50:09 | Amarin AMRN Gains As Market Dips: What You Should Know

2019-10-29 10:25:02 | Is a Beat in Store for Amarin AMRN This Earnings Season?

2019-10-25 11:32:03 | Implied Volatility Surging for Amarin AMRN Stock Options

2019-10-24 16:30:05 | Amarin to Report Third Quarter 2019 Results and Host Conference Call on November 5, 2019

2019-10-24 15:57:22 | 5 'Strong Buy' Biotech Stocks With Rapidly Approaching Catalysts

2019-10-23 10:23:00 | Hedge Funds Have Never Been More Bullish On Amarin Corporation AMRN